Intern
    Onkologische Forschung

    Ralf C. Bargou: Translational Oncology

    Summary

    Our group is interested in the development of targeted and personalized therapies for patients with tumors of the lympho-hematopoietic system. We focus on characterization of oncogenic signaling networks in multiple myeloma and their underlying genetic aberrations in a combined functional and genetic approach (cru216)
    Complementary to this, we develop T cell engaging therapies for cancer treatment in a variety of cancer entities. Our group translates the knowledge from preclinical research in these fields into the clinic and has initiated a broad early cclinical trial program ranging from leukemia to prostate cancer. The program is supported by the central CCC Trial Office and is conducted in the Early Clinical Trial Unit (ECTU) of the CCC Mainfranken.

    Recent Publications

    Topp, MS, Goekbuget, N, Zugmaier, G, Goebeler, M, Klinger, M, Neumann, S, Horst, H-A, Raff, T, Viardot, A, Schmid, M, Stelljes, M, Schaich, M, Degenhard, E, Köhne-Volland, R, Brüggemann, M, Ottmann, O, Pfeifer, H, Burmeister, T, Nagorsen, D, Schmidt, M, Lutterbuese, R, Reinhardt, C, Baeuerle, PA, Kneba, M, Einsele, E, Riethmüller, G, Hoelzer, D, Kufer, P, and Bargou, RC. Long-term follow-up of hematological relapse-free survival in a phase 2 study of blinatumomab in patients with minimal residual disease (MRD) of B-cell precursor acute lymphoblaszic leukemia (ALL). Blood, 120(26):5185-7, 2012.

    Topp, MS, Kufer, P, Goekbuget, N, Goebeler, M, Klinger, M, Neumann, S, Horst, H-A, Raff, T, Viardot, A, Schmid, M, Stelljes, M, Schaich, M, Degenhard, E, Köhne-Volland, R, Brüggemann, M, Ottmann, O, Pfeifer, H, Burmeister, T, Nagorsen, D, Schmidt, M, Lutterbuese, R, Reinhardt, C, Baeuerle, PA, Kneba, M, Einsele, E, Riethmüller, G, Hoelzer, D, Zugmaier, G, and Bargou, RC. Targeted therapy with the T-cell engaging antibody blinatumomab of chemorefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol., 29(18):2493-8, 2011.

    Steinbrunn, T., Stühmer, T., Gattenlöhner, S., Rosenwald, A., Mottok, A.., Unzicker, C., Einsele, H., Chatterjee, M., and Bargou. R. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood, 117(6):1998-2004. 2011.

    Knop, S.; Gerecke, C.; Liebisch, P.; Topp, M.S.; Platzbecker, U.; Sezer, O.; Vollmuth, C.; Falk, K.; Glasmacher, A.; Maeder, U.; Einsele, H.; and Bargou, R.C. (2009): Lenalidomide (Revlimid®); adriamycin and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: A report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 113:1160-1171.

    Bargou, R.C.; Leo, E.; Zugmaier, G.; Klinger, M.; Goebeler, M.; Knop, S.; Noppeney, R.; Viardot, A.; Hess, G.; Schuler, M.; Einsele, H.; Riethmüller, G.; Brandl, C.; Wolf, A.; Kirchinger, P.; Klappers, P.; Schmidt, M.; Reinhardt, C.; Baeuerle, P.; and Kufer, P. (2008): Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:974-977.

    Kontakt

    Comprehensive Cancer Center
    Haus C16
    Josef-Schneider Str. 6
    97080 Würzburg

    Tel.: +49 931 201-35350
    Fax: +49 931 201-35359
    E-Mail

    Suche Ansprechpartner

    Campus Medizin